Heron Therapeutics, Inc. (HRTX)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 1
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, and HRTX also fails the liquidity floors (20-day avg dollar volume $1.06M; recent 3-session avg $0.80M).
Company overview
Heron Therapeutics, Inc. is a biotechnology company focused on developing therapies for critical patient needs using its Biochronomer drug delivery platform. Its products include SUSTOL and CINVANTI, which are used to prevent chemotherapy-induced nausea and vomiting. The company is also developing ZYNRELEF for pain management and other therapies for postoperative conditions.
Fundamental
weakHeron Therapeutics has strong gross margins but remains loss-making with significant balance-sheet risks.
HRTX has built meaningful product sales (about $151M TTM) with high gross margins (~70%), but it remains loss-making (TTM net margin ~-22.5%) and free-cash-flow negative (FCF yield ~-20%). The latest SEC 10-Q highlights covenant waivers and required paydowns under its working-capital facility and discloses Nasdaq minimum-bid-price non-compliance, underscoring elevated financing and listing risk. The stock screens very cheap on sales (P/S ~0.40; EV/Sales ~1.24), but leverage, negative interest coverage and weak financial-health scores dominate the risk/reward.
Sentiment
weakSentiment is fragile due to guidance withdrawal, patent litigation, and listing compliance risks.
Near-term narrative is being driven by the Q2 results (including guidance withdrawal amid CINVANTI patent uncertainty) and follow-on negative commentary (including a sell-side downgrade), with last ~14d media sentiment bearish (polarity_score ≈ -0.31). The 30–90d baseline is too sparse for a determinate delta, and a moderate red-flag cap applies given the ongoing, court-linked CINVANTI patent litigation overhang.
Technical
very weakThe stock is in a downtrend with oversold conditions, lacking a bullish reversal signal.
HRTX is in a confirmed short-term downtrend: price is below the 20/50/200-day SMAs and 9/21-day EMAs, MACD is negative and below signal, and ADX 31.72 confirms trend strength. RSI 26.30 and Williams %R -92.82 show oversold conditions, but there is no bullish reversal confirmation and liquidity is poor.
You’re looking at 2026-08-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.